Assessing the Efficacy of Proton Pump Inhibitors in the Management of Chronic GERD

Main Article Content

1Dr Agha Syed Muhammad, 2Dr Zubair Ahmed, 3Muhammad Abdullah Khalid, 4Dr Shandana Altaf, 5Dr Ammara Zia, 6Dr Wajid Ali, 7Dr. Muhammad Faisal Nadeem, 8Raed Fawaz Fahad Alrashed, 9Kashif Lodhi


Gastroesophageal reflux disease, Proton pump inhibitors, Chronic GERD, Farooq Hospital, Efficacy, Quality of life, Adverse effects, Clinical practice, Prospective cohort study


Gastroesophageal reflux disease (GERD) is a prevalent chronic condition characterized by the reflux of gastric contents into esophagus, leading to troublesome symptoms and potential complications. Proton pump inhibitors (PPIs) are extensively agreed for management of GERD, but their efficacy in a specific clinical setting, such as Farooq Hospital, warrants investigation. Our current research aims to evaluate effectiveness of PPIs in management of chronic GERD over a period of six months.

Aim: The primary objective of our current research is to assess efficacy of proton pump inhibitors in alleviating symptoms and improving quality of life in patients with chronic GERD attending Farooq Hospital. Additionally, the study aims to explore the safety profile of PPIs over the six-month duration.

Methods: This prospective cohort study will be conducted at Farooq Hospital over a six-month period. Patients diagnosed with chronic GERD will be enrolled, and their demographic information, medical history, and baseline symptomatology will be recorded. Participants will be prescribed proton pump inhibitors according to standard clinical practice. Regular follow-ups will be scheduled to assess symptom improvement, medication adherence, and any adverse effects. Objective measures such as endoscopic findings and pH monitoring may be included in the methodology to provide a comprehensive evaluation.

Results: The results of this study will be analyzed to determine effectiveness of proton pump inhibitors in managing chronic GERD at Farooq Hospital. Outcome measures will include sign resolution, improvement in quality-of-life scores, and the incidence of adverse effects. Statistical methods such as t-tests and chi-square tests will be employed to analyze the data, and the findings will be presented descriptively.

Conclusion: The results from the current research are expected to offer valued insights into effectiveness of proton pump inhibitors in specific context of Farooq Hospital for the management of chronic GERD. The results will contribute to the existing knowledge on GERD management and may inform clinical practices at this healthcare institution. The study's conclusion will highlight the implications of the findings for patient care and potential avenues for future research in this field.

Abstract 45 | PDF Downloads 25


1. Lawate, P., Jilawar, N., Vyas, K., Pebbili, K. K., Desai, S., Rathod, R., ... & Paspulate, A. (2023). Effectiveness of Rabeprazole and Other Proton Pump Inhibitors in Managing GERD with Varying Severity: A Retrospective, Real-world EMR-based Study (POWER GERD Study). Journal of the Association of Physicians of India, 71(10), 38.
2. Carrouel, F., Dziadzko, M., Grégoire, C., Galinski, M., Dussart, C., & Lvovschi, V. E. (2023). Relevance of early management by proton-pump inhibitor in acute upper gastro-intestinal tract disorder: A scoping review. Biomedicine & Pharmacotherapy, 167, 115523.
3. Tan, J., Jeffries, S., & Carr, R. (2023). A Review of Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease in Neonates and Infants. Pediatric Drugs, 25(5), 557-576.
4. Ullah, I., Jan, N., Anjum, S., Islam, F., Marwat, A. G., & Hayat, I. (2023). Effect of Proton Pump Inhibitors on the Management of GERD in the Department of Gastroenterology HMC Peshawar. Pakistan Journal of Medical & Health Sciences, 17(05), 250-250.
5. Gross, M., Neuschwander, D., Steffens, L., Thomsen, J., & Röschmann-Doose, K. (2023). Multicentre prospective study to evaluate effectiveness and safety of gel-forming and hyaluronic-acid containing chewable tablets as add-on treatment in patients with gastroesophageal reflux disease (GERD) symptoms and unsatisfying proton pump inhibitor therapy. BMC gastroenterology, 23(1), 304.
6. Watts, K., & Taylor, M. (2023). Estimating the cost-effectiveness of proton-pump inhibitors vs over-the-counter antacids for acid reflux: an overview of methods. British Journal of Healthcare Management, 29(9), 230-233.
7. Foocharoen, C., Kingkaew, P., Teerawattananon, Y., Mahakkanukrauh, A., Suwannaroj, S., Manasirisuk, W., ... & Sangchan, A. (2023). Cost‐effectiveness of alginic acid in combination with proton pump inhibitor for the treatment of gastroesophageal reflux disease in systemic sclerosis patients. International Journal of Rheumatic Diseases, 26(10), 2037-2046.
8. King, E., Horn, D., Gluchowski, N., O'Reilly, D., Fiander, M., & Soll, R. (2023). Safety and efficacy of proton pump inhibitors in preterm infants with gastroesophageal reflux disease. The Cochrane Database of Systematic Reviews, 2023(5).
9. Abbasi, A., Siddiqui, S. A., Ram, B., Khan, J. U. A., Sheikh, K., Ali, A., ... & Qayyum, A. (2023). Real-World Evidence to Evaluate the Efficacy and Safety of Vonoprazan in Gastrointestinal Disorders in the Pakistani Population. Cureus, 15(11).
10. Swed, S., Alibrahim, H., Bohsas, H., Ibrahim, A. R., Siddiq, A., Jawish, N., ... & Wahsh12, E. A. (2023). Evaluating physicians’ awareness and prescribing trends regarding proton pump inhibitors: a cross-sectional study.
11. Tack, J., Vladimirov, B., Horny, I., Chong, C. F., Eisner, J., Czerniak, R., & Takanami, Y. (2023). Randomized clinical trial: A double‐blind, proof‐of‐concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro‐esophageal reflux disease and partial response to a healing dose of a proton‐pump inhibitor. Neurogastroenterology & Motility, 35(1), e14468.
12. Youn, Y. H., Jung, H. K., Kim, S. Y., Huh, C. W., Shin, C. M., Oh, J. H., ... & Lee, K. J. (2023). On-demand Versus Continuous Maintenance Treatment With a Proton Pump Inhibitor for Mild Gastroesophageal Reflux Disease: A Prospective Randomized Multicenter Study. Journal of Neurogastroenterology and Motility, 29(4), 460.
13. Shaykevich, A., & Tepolt, F. In adult patients with gastroesophageal reflux disease, is twice-daily proton pump inhibitor dosing more effective than once-daily dosing in relieving symptoms?. Evidence-Based Practice, 10-1097.
14. Reddy, A., Gyawali, C. P., & Patel, A. (2023). The Impact of Gastroparesis on Medical Therapy for Gastroesophageal Reflux Disease (GERD). Foregut, 26345161231211758.
15. Lesmana, E., Simadibrata, D. M., & Fass, R. (2023). S561 Vonoprazan Is Superior to a Proton Pump Inhibitor in Healing Severe Erosive Esophagitis: A Meta-Analysis of Randomized Controlled Trials. Official journal of the American College of Gastroenterology| ACG, 118(10S), S411.
16. Mari, A., Marabotto, E., Ribolsi, M., Zingone, F., Barberio, B., Savarino, V., & Savarino, E. V. (2023). Encouraging appropriate use of proton pump inhibitors: existing initiatives and proposals for the future. Expert Review of Clinical Pharmacology, 1-11.
17. Tanaka, I., Tarasawa, K., Saito, H., Hirasawa, D., Fujimori, K., Fushimi, K., & Matsuda, T. (2023). Is proton-pump inhibitor effective in preventing postoperative bleeding after esophageal endoscopic submucosal dissection?. Diseases of the Esophagus, doad060.
18. Saboo, B., Mulwani, N., Petare, A. U., Veligandla, K. C., Pinto, C. S., Mane, A., ... & Kotak, B. (2023). A real-world retrospective study of omeprazole–domperidone combination in managing acid peptic disease with PRoton-pump Inhibitors in patients with type 2 DiabEtes mellitus (PRIDE-2). Drugs in Context, 12.
19. Shah, E. D., Chan, W. W., Jodorkovsky, D., Lynch, K. L., Patel, A., Patel, D., & Yadlapati, R. (2023). Optimizing the management algorithm for heartburn in general gastroenterology: Cost-effectiveness and cost-minimization analysis. Clinical Gastroenterology and Hepatology.
20. Nguyen, P. V. Q., Boidin, C., & Bouin, M. (2023). Effectiveness of prescribing codes in reducing inappropriate proton pump inhibitors in ambulatory care. Journal of the American Pharmacists Association.
21. Durán-Rosas, C., Priego-Parra, B. A., Morel-Cerda, E., Mercado-Jauregui, L. A., Aquino-Ruiz, C. A., Triana-Romero, A., ... & Remes-Troche, J. M. (2023). Incidence of Small Intestinal Bacterial Overgrowth and Symptoms After 7 Days of Proton Pump Inhibitor Use: A Study on Healthy Volunteers. Digestive Diseases and Sciences, 1-7.
22. Dai, Y., Liu, B., Shen, X., & Huang, L. (2023). Progress in the Study of Vonoprazan Fumarate vs. Proton Pump Inhibitors in the Treatment of Gastroesophageal Reflux Disease. Yangtze Medicine, 7(2), 95-104.
23. Woo, J. Y., Pikov, V., & Chen, J. D. (2023). Neuromodulation for Gastroesophageal Reflux Disease: A Systematic Review. Journal of Translational Gastroenterology, 1(1), 47-56.
24. Malekpour, H., Noori, A., Abdi, S., Abbasinazari, M., Mahboubi, A., & Ghamsari, M. A. (2023). Is the Addition of Sublingual Melatonin to Omeprazole Superior to Omeprazole Alone in the Management of Gastroesophageal Reflux Disease Symptoms: A Clinical Trial. The Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology.
25. Kumar, V., & Chauhan, S. K. An Update On Proton-Pump Inhibitors As A Treatment Of Peptic Ulcers And Gastroesophageal Reflux Disease (Gerd).